Pneumococcal Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Conjugate Vaccines is the fastest growing sector, North America is the largest market

The global pneumococcal vaccine market is projected to expand significantly, from USD 9.71 billion in 2025 to USD 13.98 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 6.26%. This market primarily consists of conjugate and polysaccharide vaccines developed to combat Streptococcus pneumoniae. Growth is largely propelled by an increase in pneumococcal diseases, the expansion of national immunization initiatives, and a growing elderly population prone to respiratory infections, driving demand for preventative solutions across all economies.

However, high manufacturing and procurement costs pose a substantial challenge, restricting access in developing regions and impeding the complete rollout of immunization programs. Data from the World Health Organization in 2024 indicates that while 163 Member States had introduced the vaccine, achieving 67% global third-dose coverage, these disparities underscore ongoing difficulties in ensuring fair supply and funding for sustained market expansion.

Market Drivers

Two primary factors are fueling the global pneumococcal vaccine market. First, the expansion of government-led national immunization programs, especially in low- and middle-income countries where access has been limited, is a major driver. International partnerships with local governments are increasingly sharing the financial load of vaccine implementation, fostering sustainable procurement. This cost-sharing model not only ensures consistent demand for manufacturers but also promotes the inclusion of pneumococcal conjugate vaccines in routine schedules. Gavi, the Vaccine Alliance, reported in its 2024 Annual Progress Report that country co-financing for Gavi-supported vaccines hit a record US$255 million in 2024, indicating a significant rise in domestic financial commitment to immunization.

Second, the increasing geriatric population, highly susceptible to pneumococcal infections, is boosting demand for advanced prophylactic vaccines globally. As immunity weakens with age, the elderly are at a higher risk of severe invasive pneumococcal disease, necessitating focused adult vaccination efforts. Data from the Institute of Environmental Science and Research's 2024 report showed that adults aged 65 and above had the highest incidence of IPD at 34.2 per 100,000. Pharmaceutical giants like Pfizer capitalize on this demand; their Third-Quarter 2025 Results reported total revenues of $16.7 billion, partly driven by the strong performance of their Prevnar vaccine family.

Market Challenges

The most significant obstacle to the pneumococcal vaccine market's growth, particularly in lower and middle-income countries, is the elevated cost of vaccine manufacturing and procurement. The intricate biological processes involved in producing conjugate vaccines demand substantial capital, leading to high prices that burden national health budgets. This financial pressure often forces developing nations to depend on external aid for immunization programs, as they struggle to self-finance procurement. When governments face budget limitations, it results in delayed purchases or restricted rollout, directly hindering vaccine uptake and market volume growth in these crucial regions.

This financial strain is quantifiable through the increasing monetary obligations placed on developing economies. Gavi, the Vaccine Alliance, reported that in 2024, lower-income countries contributed nearly US$255 million to their own vaccination programs through co-financing, a 19% increase from the prior year. This rising financial strain highlights the ongoing difficulty for resource-limited nations to maintain widespread immunization coverage, thereby constraining the market's full expansion without continuous external financial support.

Market Trends

The pneumococcal vaccine market is undergoing significant transformation, marked by two key trends. Firstly, there's an accelerated move towards ultra-high valency conjugate vaccines, with manufacturers striving to offer broader serotype coverage beyond current 20-valent options. This shift aims to counter the "replacement phenomenon," where non-vaccine serotypes cause disease, leading to rapid development and commercialization of next-generation PCVs, particularly for adults. The market has shown strong acceptance of these broader-spectrum vaccines, as exemplified by Merck & Co., Inc.'s newly launched 21-valent vaccine, Capvaxive, which generated US$244 million in sales in Q3 2025 due to robust demand. This highlights the clinical importance of expanded valency in reducing invasive pneumococcal disease.

Secondly, the rise of cost-effective indigenous vaccine manufacturing in developing regions is disrupting the traditional dominance of Western multinational companies. Local biotechnology firms, especially in India, are rapidly increasing production to meet demand in the Global South, thus reducing dependency on external aid and mitigating international procurement delays. This strategic expansion is backed by significant investments in infrastructure and research to ensure independent supply security. For instance, Biological E. Limited committed ₹4,000 crore to establish advanced vaccine facilities, demonstrating the crucial role of such investments in providing affordable pneumococcal vaccines globally and ensuring fair access in low- and middle-income countries.

Key Market Players

• GSK PLC
• Pfizer Inc
• Merck KGaA
• Serum Institute of India Pvt Ltd
• CSL Ltd
• Sanofi SA
• Walvax Biotechnology Co., Ltd
• Beijing Minhai Biotechnology Limited Company
• AstraZeneca PLC
• BioNTech

Report Scope

In this report, the Global Pneumococcal Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pneumococcal Vaccine Market, by Type:

• Conjugate Vaccines
• Polysaccharide Vaccines

Pneumococcal Vaccine Market, by Indication:

• Bronchitis
• Meningitis
• Pneumonia
• Sepsis

Pneumococcal Vaccine Market, by Product:

• Pneumovax23
• Prevnar 13
• Synflorix

Pneumococcal Vaccine Market, by Distribution:

• Government Authorities
• Non-Governmental Organizations

Pneumococcal Vaccine Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pneumococcal Vaccine Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.